For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the arrival of Vyndamax and Tafamidis meglumine represents a significant change. These novel therapies preserve the transthyretin protein, slowing its damaging build-up and lessening the severity of the condition . People are now reporting benefits i… Read More